Danisco said the move was motivated by the strong science and regulatory backing for the ingredient in the cholesterol lowering-cardiovascular area, with emerging markets singled out as the most promising, perhaps recognising the strength of sterol leaders Cognis-BASF and Raisio in established markets like North America and western Europe.
“Danisco supports ingredients that have strong documented scientific data,” Peter Wisler, director of business development in Danisco’s health and nutrition division told NutraIngredients this morning. “There is a global focus and we see main opportunities in the future in emerging markets such as Eastern Europe and South America. We are developing applications in the areas of dietary supplements, and a range of food products including oils and fats, dairy, and baked goods, among others."
“Working with Danisco, a leading ingredient supplier, will enable them to combine their expertise with Danisco's global presence and strong application know-how.”
The global phytosterols raw materials market is estimated at €300m and growing at between 7-9%, Danisco said.
In a statement, Patrick Veau, vice president of Danisco’s health and nutrition division added:
“While markets in Europe and, to some extent, the US have seen good penetration, many parts of Asia, Eastern Europe and South America have yet to experience a broader adoption of phytosterols,”
“Danisco’s global presence and strong application know-how, combined with Arboris’ ability to supply high quality products, will ensure that no country needs to miss out on one of the most effective functional food ingredients to lower cholesterol.”
The range, will be added to Danisco’s cardiovascular platform in May this year. The company has five other health platforms: digestive, immune, bone, oral and weight management.
Danisco became the subject of a DuPont buy out bid for about €4.5bn in January which is ongoing.